What is the role of milrinone in the management of cardiogenic shock?

Label:chem

Topic
Milrinone is a phosphodiesterase inhibitor used to increase cardiac output by enhancing myocardial contractility and reducing afterload. It is primarily excreted by the kidneys, and its efficacy and safety in patients with renal dysfunction are not well-established.
Answer
Milrinone is used to improve cardiac function in patients with cardiogenic shock. However, its efficacy may be influenced by renal function, particularly in patients with acute kidney injury (AKI). The study suggests that milrinone may offer therapeutic benefits in patients without AKI, but these benefits are attenuated in patients who develop AKI.
Return to Home Chemical List
Knowledge you may be interested in
How does milrinone help in the management of cardiogenic shock in Takotsubo cardiomyopathy (TTC)? What role does tetrahydrocannabinol (THC) play in the development of Takotsubo cardiomyopathy (TTC)? How effective is the combination of intraarterial Milrinone and Nimodipine in treating severe refractory cerebral vasospasm (VSP)? What is the role of Nimodipine in treating severe refractory cerebral vasospasm (VSP) following aneurysmal subarachnoid hemorrhage (aSAH)? What is the role of Milrinone in treating severe refractory cerebral vasospasm (VSP) following aneurysmal subarachnoid hemorrhage (aSAH)? How does Milrinone potentially contribute to cancer therapy? What is the potential role of Terbutaline in cancer therapy? How do different silane coupling agents affect the shear-thinning behavior of Fe3O4/CNT silicone oil-based magnetic liquids? What is the effect of different silane coupling agents on the magneto-viscous effect of Fe3O4/CNT silicone oil-based magnetic liquids? How does the molecular structure of silane coupling agents influence the viscosity-temperature properties of Fe3O4/CNT silicone oil-based magnetic liquids? What is the role of dobutamine in the management of cardiogenic shock? How does renal function impact the efficacy of milrinone compared to dobutamine in cardiogenic shock? What are the implications of acute kidney injury (AKI) on the treatment effect of milrinone compared to dobutamine? What is the role of hcast 3-25 in the regulation of calpain-1 activity? How does hcast 3-25 interact with calpain-1 in the absence of Ca2+? What is the effect of hcast 3-25 on calpain-1 activity in the presence of inhibitory calpastatins? How does Angiotensin II (AngII) affect podocyte autophagy in hypertension-induced kidney injury? What is the role of calpastatin in preventing Angiotensin II-mediated podocyte injury? How does the deletion of Atg5 in podocytes affect the progression of Angiotensin II-induced kidney injury? What is the mechanism by which Angiotensin II inhibits autophagy in podocytes?